<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Oncohost</title>
    <link>https://www.biospace.com/employer/3076402/oncohost</link>
    <description>Oncohost</description>
    <language>en-US</language>
    <lastBuildDate>Tue, 21 Jan 2020 13:56:04 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/3076402/oncohost.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>OncoHost and RayBiotech Awarded $1 Million Grant From the BIRD Foundation to Advance Precision Oncology for Patients Receiving Immunotherapy</title>
      <link>https://www.biospace.com/oncohost-and-raybiotech-awarded-1-million-grant-from-the-bird-foundation-to-advance-precision-oncology-for-patients-receiving-immunotherapy</link>
      <description>OncoHost, global leader in host response profiling for improved personalized cancer therapy, together with its partner RayBiotech, a leading life sciences company developing high-throughput protein detection technologies for biomarker discovery initiatives, announced today the companies have been awarded a $1 million grant from the Israel-U.S</description>
      <pubDate>Tue, 21 Jan 2020 13:56:04 GMT</pubDate>
      <guid>https://www.biospace.com/oncohost-and-raybiotech-awarded-1-million-grant-from-the-bird-foundation-to-advance-precision-oncology-for-patients-receiving-immunotherapy</guid>
    </item>
    <item>
      <title>OncoHost to Present Data on Host Response Profiling for Melanoma Patients at 2020 ASCO Annual Meeting</title>
      <link>https://www.biospace.com/oncohost-to-present-data-on-host-response-profiling-for-melanoma-patients-at-2020-asco-annual-meeting</link>
      <description>OncoHost, global leader in host response profiling for improved personalized cancer therapy, announced today that its abstract on the use of advanced bioinformatic analysis and machine learning tools on plasma proteomics in order to predict outcomes of immunotherapy-treated melanoma patients was accepted for the American Society of Clinical Oncology (ASCO) 2020 Virtual Poster Discussion Session.</description>
      <pubDate>Thu, 14 May 2020 12:36:06 GMT</pubDate>
      <guid>https://www.biospace.com/oncohost-to-present-data-on-host-response-profiling-for-melanoma-patients-at-2020-asco-annual-meeting</guid>
    </item>
    <item>
      <title>OncoHost to Present Data on Host Response Profiling for NSCLC Patients at ESMO Virtual Congress 2020</title>
      <link>https://www.biospace.com/oncohost-to-present-data-on-host-response-profiling-for-nsclc-patients-at-esmo-virtual-congress-2020</link>
      <description>Clinical Study Investigates Host Response-Related Biological Processes that Relate to Immunotherapy Treatment Resistance in NSCLC Patients [17-September-2020] BINYAMINA, Israel , Sept. 17, 2020 /PRNewswire/ -- OncoHost , a global leader in host response profiling for improved personalized cancer therapy, announced today that its research on the use of its plasma prot</description>
      <pubDate>Thu, 17 Sep 2020 12:06:08 GMT</pubDate>
      <guid>https://www.biospace.com/oncohost-to-present-data-on-host-response-profiling-for-nsclc-patients-at-esmo-virtual-congress-2020</guid>
    </item>
    <item>
      <title>OncoHost to Present Data on Predicting Host Response to Immunotherapy at the MAP 2020 Virtual Congress - ESMO</title>
      <link>https://www.biospace.com/oncohost-to-present-data-on-predicting-host-response-to-immunotherapy-at-the-map-2020-virtual-congress-esmo</link>
      <description>OncoHost, a global leader in host response profiling for improved personalized cancer therapy, announced today that Professor Yuval Shaked, co-founder and Chief Scientific Advisor at OncoHost, and Professor of Cell Biology and Cancer Science at the Technion – Israel Institute of Technology,</description>
      <pubDate>Mon, 05 Oct 2020 12:06:10 GMT</pubDate>
      <guid>https://www.biospace.com/oncohost-to-present-data-on-predicting-host-response-to-immunotherapy-at-the-map-2020-virtual-congress-esmo</guid>
    </item>
    <item>
      <title>OncoHost to Present Data on Predicting Host Response to Immunotherapy in Melanoma Patients at SITC 2020</title>
      <link>https://www.biospace.com/oncohost-to-present-data-on-predicting-host-response-to-immunotherapy-in-melanoma-patients-at-sitc-2020</link>
      <description>Study Examines Plasma-Based Proteomic Profiling as a Clinically Insightful Tool for Oncologists to Identify New Targets in Overcoming Treatment Resistance</description>
      <pubDate>Mon, 09 Nov 2020 13:06:17 GMT</pubDate>
      <guid>https://www.biospace.com/oncohost-to-present-data-on-predicting-host-response-to-immunotherapy-in-melanoma-patients-at-sitc-2020</guid>
    </item>
    <item>
      <title>OncoHost Welcomes Nobel Prize Winner to Scientific Advisory Board</title>
      <link>https://www.biospace.com/oncohost-welcomes-nobel-prize-winner-to-scientific-advisory-board</link>
      <description>OncoHost, global leader in host response profiling for improved personalized cancer therapy, announced today that renowned biologist and winner of The Nobel Prize in Chemistry, Professor Aaron Ciechanover, has joined the company's scientific advisory board.</description>
      <pubDate>Mon, 11 Jan 2021 13:06:22 GMT</pubDate>
      <guid>https://www.biospace.com/oncohost-welcomes-nobel-prize-winner-to-scientific-advisory-board</guid>
    </item>
    <item>
      <title>OncoHost Secures $8 Million Series B Funding Round to Advance its AI-Powered Precision Oncology Platform</title>
      <link>https://www.biospace.com/oncohost-secures-8-million-series-b-funding-round-to-advance-its-ai-powered-precision-oncology-platform</link>
      <description>OncoHost, global leader in host response profiling for improved personalized cancer therapy, today announced the completion of a $8 million Series B funding round.</description>
      <pubDate>Tue, 19 Jan 2021 13:06:15 GMT</pubDate>
      <guid>https://www.biospace.com/oncohost-secures-8-million-series-b-funding-round-to-advance-its-ai-powered-precision-oncology-platform</guid>
    </item>
    <item>
      <title>OncoHost Publishes Data Identifying Predictive Signature for Response to Immunotherapy in Lung Cancer Patients</title>
      <link>https://www.biospace.com/oncohost-publishes-data-identifying-predictive-signature-for-response-to-immunotherapy-in-lung-cancer-patients</link>
      <description>OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has published a study identifying a predictive proteomic signature for patient response to immune checkpoint inhibitor (ICI) therapy in non-small-cell lung carcinoma (NSCLC) patients.</description>
      <pubDate>Mon, 13 Sep 2021 12:06:13 GMT</pubDate>
      <guid>https://www.biospace.com/oncohost-publishes-data-identifying-predictive-signature-for-response-to-immunotherapy-in-lung-cancer-patients</guid>
    </item>
    <item>
      <title>OncoHost to Present Data at SITC 2021 on Predicting NSCLC Patient Response to Immunotherapy Utilizing Proteomic Profiling</title>
      <link>https://www.biospace.com/oncohost-to-present-data-at-sitc-2021-on-predicting-nsclc-patient-response-to-immunotherapy-utilizing-proteomic-profiling</link>
      <description>OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has published a study identifying three distinct proteome subtypes that are associated with response from a cohort of non-small cell lung cancer (NSCLC) patients undergoing immunotherapy.</description>
      <pubDate>Fri, 12 Nov 2021 12:06:48 GMT</pubDate>
      <guid>https://www.biospace.com/oncohost-to-present-data-at-sitc-2021-on-predicting-nsclc-patient-response-to-immunotherapy-utilizing-proteomic-profiling</guid>
    </item>
    <item>
      <title>OncoHost Welcomes UC Davis Professor, David Gandara, M.D., to Scientific Advisory Board</title>
      <link>https://www.biospace.com/oncohost-welcomes-uc-davis-professor-david-gandara-m-d-to-scientific-advisory-board</link>
      <description>OncoHost, announced today that Professor David R. Gandara, director of the Thoracic Oncology Program at University of California Davis Comprehensive Cancer Center (UCDCCC), professor of medicine and senior adviser to the cancer center director, has joined the company's scientific advisory board.</description>
      <pubDate>Tue, 30 Nov 2021 13:06:19 GMT</pubDate>
      <guid>https://www.biospace.com/oncohost-welcomes-uc-davis-professor-david-gandara-m-d-to-scientific-advisory-board</guid>
    </item>
  </channel>
</rss>
